

## Avycaz<sup>®</sup> (ceftazidime/avibactam) – Expanded indications

- On January 26, 2024, the [FDA approved](#) AbbVie's [Avycaz \(ceftazidime/avibactam\)](#) for the pediatric population from birth (at least 31 weeks gestational age) for the treatment of complicated intraabdominal infections (cIAI); complicated urinary tract infections (cUTI), including pyelonephritis; and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
  - Avycaz was previously approved for these indications in pediatric patients aged 3 months and older.
- The approval of Avycaz for the expanded indications was supported by evidence from adequate and well-controlled studies of Avycaz in adults with cUTI, cIAI, and HABP/VABP and additional pharmacokinetic and safety data from pediatric trials.
- The most common adverse reactions (> 3%) with Avycaz use in pediatric patients less than 3 months of age were vomiting and increased transaminases.
- The recommended dose of Avycaz for the treatment of pediatric patients greater than 28 days to less than 3 months is 37.5 mg/kg every 8 hours via intravenous (IV) infusion. In pediatric patients less than or equal to 28 days with gestational age of at least 31 weeks, the recommended dose is 25 mg/kg every 8 hours via IV infusion. The duration of treatment ranges from 5 to 14 days, depending on the infection.
  - Refer to the Avycaz drug label for complete dosing and administration recommendations.